
Nectar Lifesciences Q2 Results FY27: Back to Rs 2.72 Cr PAT from Loss, Revenue Rs 0.01 Cr
Updated: 14 Nov 2026 • 2:12 pm
Posted by:

Quick Answer
Nectar Lifesciences Q2 Results FY27 were declared on 14 November 2026, with consolidated revenue of Rs 0.01 Cr, down 99.8% YoY from Rs 5 Cr. Net profit came in at Rs 2.72 Cr against a loss of Rs 176.01 Cr a year earlier, a 101.55% YoY change. These quarterly results show YoY growth in net profit alongside a much smaller top line, with an Operating Profit loss of Rs 6.68 Cr.
Nectar Lifesciences Ltd (NECLIFE) Q2 Results FY27 announced on 14 November 2026, covering the company's financial performance for the July to September quarter. The results date brought consolidated revenue of Rs 0.01 Cr against Rs 5 Cr a year earlier, and net profit (PAT) of Rs 2.72 Cr against a loss of Rs 176.01 Cr. Nectar Lifesciences Q2 Results FY27 are reported on a consolidated basis, so these consolidated results cover the whole group.
This Nectar Lifesciences Q2 Results analysis covers the financial highlights, business drivers, outlook and risks behind the numbers. The results analysis below sets each current figure beside the same quarter last year, and it begins with the Financial Highlights table.
Click Here – Get Free Investment Predictions
Nectar Lifesciences Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 0.01 Cr | Rs 5 Cr | -99.8% YoY |
| Operating Profit | Rs -6.68 Cr | Rs -1.04 Cr | -542.31% YoY |
| Net Profit (PAT) | Rs 2.72 Cr | Rs -176.01 Cr | +101.55% YoY |
Source: company filing for Nectar Lifesciences Q2 Results FY27, 14 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Nectar Lifesciences Q2 Results: What Stands Out
- Consolidated revenue: revenue fell 99.8% YoY to Rs 0.01 Cr from Rs 5 Cr in the year-ago quarter.
- Net profit: net profit of Rs 2.72 Cr replaced a Rs 176.01 Cr loss, a 101.55% YoY change in the bottom line.
- Operating Profit: the Operating Profit loss widened from Rs 1.04 Cr to Rs 6.68 Cr, a 542.31% YoY move in the wrong direction.
- Nectar Lifesciences Q2 Results FY27: the company returned to a net profit from a loss, while revenue stayed at Rs 0.01 Cr.
- Next step: the performance analysis below lines up these contrasting figures to show how the quarter fits together.
Nectar Lifesciences Q2 Results FY27: Performance Analysis
Nectar Lifesciences Q2 Results FY27 show consolidated revenue of Rs 0.01 Cr and net profit of Rs 2.72 Cr for Q2 FY27. Revenue fell 99.8% YoY from Rs 5 Cr, while net profit swung from a loss of Rs 176.01 Cr. The Operating Profit loss widened from Rs 1.04 Cr to Rs 6.68 Cr.
The Nectar Lifesciences Q2 Results FY27 pattern is a very small top line paired with a positive bottom line. In this results analysis, revenue is Rs 4.99 Cr lower than a year ago, while net profit is Rs 178.73 Cr higher, and the Operating Profit loss is Rs 5.64 Cr larger.
Nectar Lifesciences Q2 Results will be read against this YoY growth in net profit and the wider Operating Profit loss. Investors following these quarterly results on the Univest app can compare the same fields in later filings, which is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Return to Net Profit – The results analysis starts with the swing itself. The company returned to a net profit of Rs 2.72 Cr from a loss in the comparison quarter, even as revenue stood at only Rs 0.01 Cr.
Net Profit Margin – Net profit margin improved to 27200.0% from -3520.2% in the comparison quarter. For Nectar Lifesciences Q2 Results FY27, this ratio reflects net profit of Rs 2.72 Cr set against a very small revenue base of Rs 0.01 Cr.
Low Debt Position – The company is almost debt free, with a debt-to-assets ratio of 0.00 in FY26. The disclosed data does not tie this to the quarter's profit, so these quarterly results treat it as balance sheet context only.
FY27 Outlook After Nectar Lifesciences Q2 Results
Full-year FY27 results will depend on the quarters that follow and on disclosed sector conditions. This results analysis therefore treats Q2 as one data point, with revenue of Rs 0.01 Cr and net profit of Rs 2.72 Cr as the base for later comparison.
Nectar Lifesciences Q2 Results FY27 give investors a consolidated reference point for the second half of the year. Whether net profit of Rs 2.72 Cr repeats, and whether the Operating Profit loss of Rs 6.68 Cr changes, will be visible only in later filings, which brings the discussion to the risks.
Key Risks to Watch After Nectar Lifesciences Q2 Results FY27
Revenue Decline
Revenue declined 99.8% year on year to Rs 0.01 Cr in the latest quarter, from Rs 5 Cr. Nectar Lifesciences Q2 Results FY27 show profit and revenue moving in very different directions, which investors can track in future filings.
Negative Return on Equity
Return on equity was low at -7.46% in FY26. Any YoY growth in net profit will need to be read against this negative return base when later quarterly figures are published.
Negative Return on Capital Employed
Return on capital employed was modest at -4.75% in FY26. Investors can compare this ratio with future disclosures to see whether capital is being used more productively over time.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Nectar Lifesciences Q2 Results FY27 show consolidated revenue of Rs 0.01 Cr, down 99.8% YoY, and net profit of Rs 2.72 Cr against a loss a year earlier. These quarterly results pair a very small top line with a positive bottom line in the consolidated results. Nectar Lifesciences Q2 Results should be read with the risks above, and investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Nectar Lifesciences Q2 Results FY27
What are Nectar Lifesciences Q2 Results FY27?
Ans. Nectar Lifesciences Q2 Results FY27 are the consolidated quarterly results for July to September 2026, declared on 14 November 2026. Alongside the results date, the Quick Answer gives revenue of Rs 0.01 Cr and net profit of Rs 2.72 Cr.
What is the results date for Nectar Lifesciences Q2 Results FY27?
Ans. The results date for Nectar Lifesciences was 14 November 2026, when the company declared its Q2 FY27 numbers. This is why the introduction and the Quick Answer both anchor the consolidated figures to that date.
What revenue was reported in Nectar Lifesciences Q2 Results FY27?
Ans. Nectar Lifesciences Q2 Results FY27 show consolidated revenue of Rs 0.01 Cr, compared with Rs 5 Cr a year earlier, which means revenue is lower by Rs 4.99 Cr, as the Financial Highlights table presents.
What net profit was reported in Nectar Lifesciences Q2 Results FY27?
Ans. Net profit in Nectar Lifesciences Q2 Results FY27 was Rs 2.72 Cr, while the year-ago quarter showed a loss of Rs 176.01 Cr, so the bottom line moved by Rs 178.73 Cr, as the Performance Analysis explains.
How much YoY growth did revenue show in Nectar Lifesciences Q2 Results FY27?
Ans. Revenue declined 99.8% YoY in Nectar Lifesciences Q2 Results FY27, while net profit moved from a loss to a profit with a 101.55% YoY change, which the Key Takeaways section lists bullet by bullet.
Did net profit rise or fall in Nectar Lifesciences Q2 Results?
Ans. Nectar Lifesciences Q2 Results show net profit rose to Rs 2.72 Cr from a loss of Rs 176.01 Cr, while revenue fell 99.8%, a contrast the Performance Analysis section describes in detail.
What was the Operating Profit in Nectar Lifesciences Q2 Results FY27?
Ans. Operating Profit in Nectar Lifesciences Q2 Results FY27 was a loss of Rs 6.68 Cr against a loss of Rs 1.04 Cr a year earlier, so the loss widened, as the Key Takeaways section notes.
Are Nectar Lifesciences Q2 Results consolidated results or standalone results?
Ans. Nectar Lifesciences Q2 Results are consolidated results, which cover the company and its subsidiaries together, while the Quick Answer and the Financial Highlights table carry the same consolidated basis.
What business factors shaped Nectar Lifesciences Q2 Results FY27?
Ans. Disclosed factors in Nectar Lifesciences Q2 Results FY27 include the return to a net profit of Rs 2.72 Cr, a net profit margin of 27200.0% and a debt-to-assets ratio of 0.00 in FY26, as the Key Business Factors section covers.
What are the key risks after Nectar Lifesciences Q2 Results FY27?
Ans. Risks after Nectar Lifesciences Q2 Results FY27 include the 99.8% revenue decline, return on equity of -7.46% and return on capital employed of -4.75% in FY26, as listed in the Key Risks section.
What is the outlook after Nectar Lifesciences Q2 Results?
Ans. Full-year FY27 results for Nectar Lifesciences will depend on the quarters that follow, so Q2 revenue of Rs 0.01 Cr and net profit of Rs 2.72 Cr serve as the base, as the Outlook section explains.
Where can I find the complete Nectar Lifesciences Q2 Results FY27 data?
Ans. The complete Nectar Lifesciences Q2 Results FY27 data sits in the Financial Highlights table above, while the Univest Screener and Univest app let readers compare these consolidated figures with other filings.
Recent Articles

Medicamen Biotech Q2 Results FY27: Revenue Up 10.18% to Rs 46.53 Cr, PAT Rises to Rs 2.35 Cr
14 November 2026

Deccan Gold Mines Q2 Results FY27: PAT Rs 6.49 Cr Against a Loss a Year Ago, Revenue Rs 17.24 Cr
14 November 2026

Munjal Auto Industries Q2 Results FY27: Revenue Up 38.55% to Rs 809.28 Cr, PAT Falls 31.96% to Rs 7.62 Cr
14 November 2026

Insolation Energy Q2 Results FY27: Revenue Up 101.64% to Rs 836.53 Cr, PAT Falls 32.18% to Rs 25.06 Cr
14 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Medicamen Biotech Q2 Results FY27: Revenue Up 10.18% to Rs 46.53 Cr, PAT Rises to Rs 2.35 Cr
Deccan Gold Mines Q2 Results FY27: PAT Rs 6.49 Cr Against a Loss a Year Ago, Revenue Rs 17.24 Cr
Munjal Auto Industries Q2 Results FY27: Revenue Up 38.55% to Rs 809.28 Cr, PAT Falls 31.96% to Rs 7.62 Cr
Insolation Energy Q2 Results FY27: Revenue Up 101.64% to Rs 836.53 Cr, PAT Falls 32.18% to Rs 25.06 Cr
John Cockerill India Q2 Results FY27: PAT Rs 11.11 Cr Against a Loss a Year Ago, Revenue Rs 315.58 Cr

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





